Previously, we showed that targeting of chemokine receptors, CXCR1 and CXCR2, in malignant melanoma by small-molecule antagonists led to reduced tumour growth, invasion, and angiogenesis (Singh et al, 2009). Here, CXCR2 is linked to melanoma.